BR9916209A - Cadeia de receptor de citocina - Google Patents

Cadeia de receptor de citocina

Info

Publication number
BR9916209A
BR9916209A BR9916209-1A BR9916209A BR9916209A BR 9916209 A BR9916209 A BR 9916209A BR 9916209 A BR9916209 A BR 9916209A BR 9916209 A BR9916209 A BR 9916209A
Authority
BR
Brazil
Prior art keywords
receptor chain
cytokine receptor
receptors
methods
chain
Prior art date
Application number
BR9916209-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Mary Collins
Debra Donaldson
Lori Fitz
Tamlyn Neben
Matthewj Whitters
Clive Wood
Marsha Wills-Karp
Original Assignee
Genetics Inst
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22786499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9916209(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst, Univ Johns Hopkins filed Critical Genetics Inst
Publication of BR9916209A publication Critical patent/BR9916209A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9916209-1A 1998-12-14 1999-12-13 Cadeia de receptor de citocina BR9916209A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21133598A 1998-12-14 1998-12-14
PCT/US1999/029493 WO2000036103A1 (en) 1998-12-14 1999-12-13 Cytokine receptor chain

Publications (1)

Publication Number Publication Date
BR9916209A true BR9916209A (pt) 2001-12-26

Family

ID=22786499

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916209-1A BR9916209A (pt) 1998-12-14 1999-12-13 Cadeia de receptor de citocina

Country Status (16)

Country Link
US (1) US7507706B1 (https=)
EP (1) EP1141286B1 (https=)
JP (3) JP5519087B2 (https=)
CN (2) CN104611339A (https=)
AT (1) ATE342976T1 (https=)
AU (1) AU780031B2 (https=)
BR (1) BR9916209A (https=)
CA (1) CA2356779C (https=)
CY (1) CY1107657T1 (https=)
DE (1) DE69933696T2 (https=)
DK (1) DK1141286T3 (https=)
ES (1) ES2277460T3 (https=)
MX (1) MXPA01006006A (https=)
NZ (1) NZ512942A (https=)
PT (1) PT1141286E (https=)
WO (1) WO2000036103A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
PT1141286E (pt) 1998-12-14 2007-01-31 Genetics Inst Llc Cadeia de receptores de citocina
WO2002055100A2 (en) * 2000-10-20 2002-07-18 Genetics Institute, Llc Method and composition for inhibition of tumor growth and enhancing an immune response
US20040209806A1 (en) * 2003-01-17 2004-10-21 Children's Hospital Medical Center Regulation of allergen induced gene
US20040198686A1 (en) * 2003-01-18 2004-10-07 Rothenberg Marc Elliot Regulation of allergen induced gene
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004092404A2 (en) * 2003-04-11 2004-10-28 Wyeth Inhibitors of acidic mammalian chitinase as asthma therapeutics
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
US20070178520A1 (en) * 2004-02-27 2007-08-02 Barbara Wolff-Winiski Screening assay for modulators of interaction between interleukin-12 and/or -23 with their receptors
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
BRPI0810561A2 (pt) * 2007-04-23 2019-09-24 Wyeth Corp métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
WO2008153790A2 (en) * 2007-05-29 2008-12-18 University Of Cincinnati Methods of modulating inflammation and compositions therefore
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
US11970526B2 (en) 2017-04-21 2024-04-30 Elanco Us Inc. IL4/IL13 receptor molecule for veterinary use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1989004838A1 (en) 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5011778A (en) 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
ES2085983T3 (es) 1989-12-20 1996-06-16 Schering Corp Antagonistas de anticuerpos de la interleuquina-4 humana.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5246701A (en) 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
HU217099B (hu) 1991-03-29 1999-11-29 Elf Sanofi Sa. Eljárás citokin típusú aktivitással rendelkező fehérje, azt kódoló rekombináns DNS-szekvencia és a megfelelő transzformált sejtek és mikroorganizmusok előállítására
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
EP0656947A1 (en) 1992-08-21 1995-06-14 Schering Corporation Human interleukin-13
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
DK0721469T3 (da) 1993-09-02 2000-05-01 Dartmouth College Anti-gp39-antistoffer og anvendelse deraf
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5696234A (en) 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
WO1997015663A1 (en) 1995-10-23 1997-05-01 Amrad Operations Pty. Ltd. A novel haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
AU2326097A (en) * 1996-03-13 1997-10-01 Zymogenetics Inc. Cytokine-receptor expressed in testis cells
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
WO1997047742A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1997047741A1 (en) 1996-06-12 1997-12-18 Smithkline Beecham Corporation Hr-1 receptor
WO1998010638A1 (en) * 1996-09-10 1998-03-19 Amrad Operations Pty. Ltd. Therapeutic molecules
GB9625899D0 (en) 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
KR20000070034A (ko) 1997-01-10 2000-11-25 아스트루 마이클 제이 항 ｃｄ40ｌ 화합물로 신염성 루푸스를 치료하는 방법
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
GB9723553D0 (en) 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
PT1141286E (pt) 1998-12-14 2007-01-31 Genetics Inst Llc Cadeia de receptores de citocina
AU5756100A (en) 1999-06-21 2001-01-09 Genetics Institute Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
AU2000278349A1 (en) 1999-09-28 2001-04-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 13 gene
AU7863900A (en) 1999-10-06 2001-05-10 Penn State Research Foundation, The Il13 mutants
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
EP2990420B1 (en) 2000-05-26 2016-12-21 Immunex Corporation Use of interleukin-4 receptor antibodies and compositions thereof

Also Published As

Publication number Publication date
WO2000036103A1 (en) 2000-06-22
ATE342976T1 (de) 2006-11-15
MXPA01006006A (es) 2004-08-12
JP2003511007A (ja) 2003-03-25
JP2010263889A (ja) 2010-11-25
EP1141286A1 (en) 2001-10-10
CA2356779A1 (en) 2000-06-22
AU2177500A (en) 2000-07-03
NZ512942A (en) 2004-01-30
DE69933696D1 (de) 2006-11-30
CA2356779C (en) 2012-03-13
EP1141286B1 (en) 2006-10-18
CN1352686A (zh) 2002-06-05
EP1141286A4 (en) 2002-06-26
WO2000036103A9 (en) 2002-04-11
PT1141286E (pt) 2007-01-31
DK1141286T3 (da) 2007-02-19
DE69933696T2 (de) 2007-08-23
JP5519087B2 (ja) 2014-06-11
AU780031B2 (en) 2005-02-24
US7507706B1 (en) 2009-03-24
CY1107657T1 (el) 2013-04-18
CN104611339A (zh) 2015-05-13
ES2277460T3 (es) 2007-07-01
JP2014113165A (ja) 2014-06-26

Similar Documents

Publication Publication Date Title
BR9916209A (pt) Cadeia de receptor de citocina
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
AU2002305450A1 (en) Proteomimetic compounds and methods
DK0910647T3 (da) Human DNase i hyperaktive varianter
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
IS4311A (is) Setin 1H-imíðazól, aðferð til framleiðslu þeirra og notkun þeirra
UA49796C2 (uk) Ангідрат пароксетин гідрохлориду, спосіб його одержання, сольвати пароксетин гідрохлориду, спосіб їх одержання, спосіб лікування та/або профілактики та фармацевтична композиція
NO963850D0 (no) Heterosykliske forbindelser, deres fremstilling og anvendelse
DE69831500D1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
NO990913L (no) Naftylforbindelser, intermediater, sammensetninger og metoder for anvendelse
DK0811068T3 (da) Humane DNase I varianter
EP1009421A4 (en) METHODS AND COMPOSITIONS FOR IMPROVING HEALING INJURIES
UA33041A (uk) Спосіб остеосинтезу переломів виросту плечової кістки
MX9704618A (es) Receptor de la interlucina-11 humana.
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar
MD599B2 (en) Method for combined osteorrhaphy of tubular fractured fragments

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]